MedTrace Logo

Effects of One HIIT Session on Adiponectin Isoforms

NCT07146867 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-05-05

No results posted yet for this study

Summary

The goal of this observational quasi-experimental study is to evaluate whether a single session of high-intensity interval training (HIIT) can acutely modulate metabolic markers, particularly adiponectin isoforms, in insufficiently active young adults (men and women, 18-29 years, free of cardiometabolic disease).

The main questions it aims to answer are:

Does a single HIIT session increase circulating medium- and high-molecular-weight adiponectin?

Does HIIT acutely alter lipid and glucose metabolism markers such as non-HDL cholesterol, insulin, and lactate?

Participants completed the following tasks:

Underwent baseline assessments (anthropometry, body composition, and resting cardiovascular parameters).

Performed one HIIT session consisting of six 3-minute intervals at 80% heart rate reserve, each followed by 3 minutes of active recovery.

Provided blood samples before and immediately after exercise to analyze adiponectin isoforms (LMW, MMW, HMW) via Western blot and to measure glucose, insulin, lipid profile, liver enzymes, and lactate.

Summary of findings:

A single HIIT session significantly increased medium-molecular-weight adiponectin (\~19%), decreased the HMW/MMW ratio, and elevated lactate and non-HDL cholesterol. No significant changes were observed in LMW or HMW adiponectin. These results suggest that MMW adiponectin is an early, sensitive marker of acute exercise response in sedentary young adults, though further research is needed to confirm long-term implications

Conditions

  • Inactivity, Physical

Interventions

BEHAVIORAL

High intensity interval training (exercise)

One 30 minute session of high intensity interval training

Sponsors & Collaborators

  • Universidad San Sebastián

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-12-01
Completion
2025-01-15

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07146867 on ClinicalTrials.gov